On November 26, 2019 ExCellThera Inc., an advanced biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, reported that data from a Phase I/II clinical trial using its lead technology, ECT-001, will be presented at the 61st Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) in Orlando, Florida (Press release, ExCellThera, NOV 26, 2019, View Source [SID1234551699]). Details of the presentation are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Date & Time: Sunday, December 8, 2019; 6:00-8:00 p.m. ET
Title: UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies
Abstract Number: 3245
Lead Author: Sandra Cohen, MD, FRCP(C), Division of Hematology and Medical Oncology, Stem Cell Transplant Program, Department of Medicine, University of Montreal and Maisonneuve-Rosemont Hospital, Montreal, QC, Canada
Location: Orange County Convention Center, Hall B
About ECT-001
The ECT-001 technology is a combination of a small molecule, UM171, and an optimized culture system. The technology, capable of expanding the number of stem and immune cells exponentially in as little as seven days, is used in novel curative cord blood transplant therapies for patients with blood cancers, allowing rapid engraftment, greatly reduced incidence of transplant-related mortality, low risk of chronic graft-versus-host disease and low risk of relapse, resulting in better outcomes for patients.